

April 4, 2024  
Web Announcement 3326

## Silver State Scripts Board (SSSB) Made Changes to Preferred Drug List (PDL) Effective April 4, 2024

The Silver State Scripts Board (SSSB) met on March 21, 2024 and voted to adopt the following changes to the Nevada Medicaid Preferred Drug List (PDL) effective April 4, 2024.

The complete PDL is posted on the [“Preferred Drug List”](#) webpage.

Drug Class/Program	Changes
Phosphate Binding Agents	Renagel® removed from PDL due to manufacturer discontinuation Xphozah® added as non-preferred
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors and Combinations	dapagliflozin added as non-preferred dapagliflozin/metformin ER added as non-preferred
Uterine Disorder Treatment	Myfembree® added as preferred OriaHnn® added as preferred Orilissa® added as preferred
ADHD Agents	Methylin® solution added as preferred
Otic Quinolones	ciprofloxacin/dexamethasone moved to preferred
Beta-Blockers	Bystolic® removed from PDL due to manufacturer discontinuation nebivolol moved to preferred nadolol moved to preferred Corgard® added as non-preferred pindolol moved to non-preferred
Serotonin-Receptor Agonists (Triptans)	Imitrex® nasal spray removed from PDL due to manufacturer discontinuation sumatriptan nasal spray moved to preferred rizatriptan tablet moved to preferred zolmitriptan ODT moved to non-preferred
Ophthalmic Anti-infective/Anti-inflammatory Combinations	tobramycin/dexamethasone suspension moved to preferred Zylet® moved to non-preferred
Immunomodulators: Atopic Dermatitis	Protopic® topical removed from PDL due to manufacturer discontinuation tacrolimus topical moved to preferred